NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Episodes

NRx Pharmaceuticals Urges FDA to Ban Benzethonium Chloride from Ketamine Products

NRx Pharmaceuticals, listed on NASDAQ as NRXP, has filed a Citizen Petition asking the FDA to prohibit the use of benzethonium chloride in ketamine products due to its toxic nature. The company has presented evidence supporting the safety and stability of their preservative-free ketamine, 'NRX-100', and is also seeking FDA approval for their oral NMDA-targeting drug, 'NRX-101'. Learn more about NRx Pharmaceuticals and stay updated on industry news at PsychedelicNewsWire.com.

Published: 2025-08-22 18:20:30

Duration: 00:02:11

Advancements in Incannex Healthcare Inc.: Positive Phase 2 Results and Strong Valuation Potential

Stonegate Capital Partners' updated coverage on Incannex Healthcare Inc. highlights the positive Phase 2 study results of their IHL-42X asset, showing significant reduction in Apnoea-Hypopnoea Index. Patient-reported outcomes were also impressive, boosting IXHL's prospects for bringing IHL-42X to market. The company's financial position has improved through strategic financing, and other projects like PSX-001 and IHL-675A are progressing well. Stonegate's valuation model suggests a range of $1.05 to $2.86 for IXHL, with potential for re-ratings based on new information.

Published: 2025-08-21 09:53:05

Duration: 00:02:09

Cybin Inc. Reports Promising Results and Shareholder Meeting Summary

Cybin Inc., a neuropsychiatry company, discussed developments in innovative mental health treatments at their recent shareholder meeting, with a focus on promising data for CYB003 and CYB004. Shareholders representing nearly half of the company's common shares were present. Visit Cybin's newsroom for further details.

Published: 2025-08-19 09:16:44

Duration: 00:01:53

Cybin Inc. Reports Q1 2025 Results and Progress in Depression and Anxiety Studies

Cybin Inc., a clinical-stage neuropsychiatry company, shared its Q1 2025 results and updates on its Phase 3 Depression Program and Phase 2 Anxiety Study. The company has expanded its Phase 3 program for major depressive disorder and is close to completing enrollment for its anxiety study. With adequate funding, Cybin is poised to address the pressing need for improved mental health treatments.

Published: 2025-08-14 18:28:22

Duration: 00:02:04

NRx Pharmaceuticals' HOPE Therapeutics(TM) Expands Network and Expertise with Acquisition of Dura Medical LLC

NRx Pharmaceuticals' subsidiary HOPE Therapeutics(TM) has received regulatory clearance in Florida to acquire Dura Medical LLC, a clinic specializing in mental health and chronic pain treatment. This acquisition will enhance HOPE's presence in Florida and strengthen their capabilities in utilizing psychedelic medications and neuroplastic technologies to treat depression and PTSD. NRx Pharmaceuticals is also progressing with filing for Accelerated Approval for NRX-101 and has submitted applications for NRX-100 and ketamine.

Published: 2025-08-08 18:21:14

Duration: 00:02:17

Cybin Inc. Receives European Approval for Phase 3 Study on CYB003 for Major Depressive Disorder

Cybin Inc. has obtained approval to launch the EMBRACE Phase 3 study in Ireland, Poland, and Greece as part of their PARADIGM program. The study will evaluate the efficacy of CYB003, a proprietary deuterated psilocin analog, in treating Major Depressive Disorder by enrolling 330 participants across various international sites. Visit www.cybin.com for more information on Cybin and its innovative mental healthcare research pipeline.

Published: 2025-08-07 18:21:18

Duration: 00:02:05

Revolutionizing Mental Healthcare: Cybin's CEO to Speak at Growth Conference

Cybin Inc., a neuropsychiatry company, will have CEO Doug Drysdale participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. Cybin is dedicated to developing new treatment options for mental health conditions, with ongoing studies on major depressive disorder and generalized anxiety disorder. A live webcast of the event will be available, showcasing Cybin's commitment to transforming mental healthcare.

Published: 2025-08-06 09:22:36

Duration: 00:02:00

Exploring Neuroplasticity in CNS Disorders with NRx Pharmaceuticals CEO

NRx Pharmaceuticals CEO Prof. Jonathan Javitt will discuss the use of ketamine and other drugs for treating CNS disorders like depression, suicidality, and PTSD at the upcoming BTIG Virtual Biotechnology Conference. The company is focused on developing therapeutics for conditions such as bipolar depression and PTSD, with plans to file for Accelerated Approval for NRX-101 and NRX-100.

Published: 2025-07-29 18:25:40

Duration: 00:02:07

Cybin Inc. Receives UK Approval for Phase 3 Trial in Depression

Cybin Inc. has obtained approval to commence the second Phase 3 trial for CYB003 in Depression, aiming to enroll 330 patients globally. With a focus on psychedelic-based treatments, the company seeks to address the growing demand for innovative mental health therapies, following the success of esketamine in the sector.

Published: 2025-07-17 09:18:25

Duration: 00:02:05

NRx Pharmaceuticals Applies for FDA Priority Voucher for NRX-100

NRx Pharmaceuticals, trading as NRXP on NASDAQ, has submitted an application for the FDA Commissioner’s National Priority Voucher for their IV Ketamine product, NRX-100. The company's focus on U.S.-based manufacturing and pursuit of a patent on their preservative-free process could enhance their competitive edge in treating suicidal depression and PTSD.

Published: 2025-06-27 18:13:56

Duration: 00:01:56

Advancing FDA-Designated Therapies: NRx Pharmaceuticals Collaborates with IBN for Corporate Communications Strategy

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) partners with IBN to enhance investor awareness as it progresses with FDA-designated therapies NRX-100 and NRX-101 for suicidal depression, chronic pain, and PTSD. The company's NMDA platform shows promise in treating central nervous system disorders, with plans for an NDA filing for NRX-100 and a public spin-out of subsidiary HOPE Therapeutics. Stay updated on NRXP developments at https://ibn.fm/NRXP

Published: 2025-06-25 09:32:56

Duration: 00:01:52

Psyence Biomedical Chief to Speak at Psychedelic Science 2025 Conference

Mary-Elizabeth Gifford, Chief of Global Impact at Psyence Biomedical Ltd., will be a featured speaker at Psychedelic Science 2025, discussing business ethics in the realm of psychedelic research. Psyence Biomedical is a Nasdaq-listed biopharma company focusing on nature-derived psilocybin medicine for FDA approval.

Published: 2025-06-18 18:15:12

Duration: 00:02:01

Advancements in Cybin Inc.'s Phase 3 Psychedelic Therapeutics Program

Cybin Inc. provided an update on its Phase 3 Psychedelic Therapeutics Program, highlighting progress in the clinical pipeline, with the lead candidate CYB003 advancing into Phase 3 development. CEO Doug Drysdale expressed confidence in the company's IP portfolio and clinical strategy, noting positive shifts in regulatory sentiment as a key factor in expediting the review process. Cybin is focused on creating safe and effective psychedelic-based therapeutics for mental health conditions like major depressive disorder and generalized anxiety disorder.

Published: 2025-06-13 09:53:28

Duration: 00:02:02

Innovations in Psychedelic Therapeutics: Updates from Cybin Inc., NRx Pharmaceuticals Inc., and Silo Pharma Inc.

Cybin Inc. CEO Doug Drysdale will be speaking at the H.C. Wainwright Neuro Perspectives Conference and the Psychedelic Science 2025 Conference, highlighting the company's focus on developing psychedelic-based therapeutics for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. has filed an application for a preservative-free ketamine formulation to address the shortage of ketamine in the U.S., and Silo Pharma Inc. has received a patent related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders, strengthening its position in the field of psychedelic therapeutics.

Published: 2025-06-12 20:18:48

Duration: 00:04:52

NRx Pharmaceuticals Announces Acquisition of Kadima Neuropsychiatry Institute and Plans to Launch $100 Million Psychiatry Clinic Network

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has acquired Kadima Neuropsychiatry Institute to establish a network of interventional psychiatry clinics. The subsidiary, HOPE Therapeutics, aims to open up to 30 clinics by 2025, with a projected $100 million run rate. NRx has also filed an ANDA for its preservative-free IV ketamine formulation, NRX-100, targeting the U.S. ketamine market and seeking to broaden its label for treating suicidal depression.

Published: 2025-06-05 18:24:54

Duration: 00:03:13

Empower Your Audience with Rythmia: Join the Affiliate Program Today!

Rythmia Life Advancement Center's new affiliate program targets wellness influencers, healers, and marketers to promote its life-changing experiences in Costa Rica. Offering competitive commissions and second-tier referral earnings, partners can share in Rythmia's mission of healing and transformation while earning income. Visit Rythmia's website for more details on this unique opportunity.

Published: 2025-06-03 18:28:25

Duration: 00:02:35

Cybin Inc. Secures U.S. Patent for CYB004 Anxiety Treatment Candidate

Cybin Inc. has obtained a U.S. patent for its CYB004 anxiety treatment candidate, extending exclusivity through 2040. CEO Doug Drysdale emphasized the potential of CYB004 to provide rapid-acting, short-duration treatment with a patient-friendly delivery system. The compound is in Phase 2 trials, projected to conclude by mid-2025, solidifying Cybin's position as a frontrunner in innovative mental health therapies.

Published: 2025-06-03 09:28:29

Duration: 00:01:57

Biotech Updates: Incannex Healthcare, Lophora, and NRx Pharmaceuticals

Stonegate Capital Partners provided an update on Incannex Healthcare Inc., reporting reduced expenses and strengthened financial position. Lophora initiated a Phase 1 trial for LPH-5 targeting CNS disorders, aiming to provide therapeutic benefits without hallucinogenic effects. NRx Pharmaceuticals announced a $10.3 million financing to expand its HOPE Clinic Network and advance FDA drug approval for neuroplastic therapies.

Published: 2025-05-28 22:50:47

Duration: 00:03:58

Advancement in PTSD Treatment: Silo Pharma's Nasal Spray Device Study

Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studies, including a toxicology study and a large animal safety trial as requested by the FDA.

Published: 2025-05-21 14:31:19

Duration: 00:01:56

Advancements in Psychedelic Therapeutics: Cybin Inc., Republican Lawmakers, and Silo Pharma Inc.

Cybin Inc. is making progress in Phase 3 and Phase 2 trials for psychedelic therapeutics targeting mental health conditions, supported by FDA approval. Republican lawmakers like Rep. Morgan Luttrell are advocating for therapeutic use of psychedelics for veterans, while Silo Pharma Inc. recently closed a public offering to fund their research in psychiatric disorders and CNS diseases.

Published: 2025-05-20 12:47:06

Duration: 00:03:51

Biopharmaceutical Companies Silo Pharma Inc. and NRx Pharmaceuticals, Inc. Make Advancements in Drug Development and Financials

Silo Pharma Inc. has priced a public offering of common stock and warrants to raise $2 million, supporting its work on therapeutic treatments for psychiatric disorders and chronic pain. Meanwhile, NRx Pharmaceuticals, Inc. reported a Q1 net loss decrease, progress on ketamine and bipolar depression treatments, and funding for its psychiatry clinic subsidiary.

Published: 2025-05-16 22:08:26

Duration: 00:03:12

Advancements in Psychedelic-Based Therapeutics by Cybin Inc., Silo Pharma Inc., and NRx Pharmaceuticals Inc.

Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health conditions.

Published: 2025-05-16 00:23:56

Duration: 00:05:27

Advancing Research on THC-Infused Beverages and Protecting Access to 7-OHM: Industry Initiatives in Focus

Love Yer Brain, part of Iconic Tonics, is collaborating with MoreBetter to study the impact of THC-infused beverages, aiming to provide insights into consumer preferences for alcohol alternatives. Meanwhile, the 7-HOPE Alliance has been established to protect legal access to 7-hydroxymitragynine (7-OHM) and promote responsible usage through science and advocacy efforts.

Published: 2025-05-07 22:58:50

Duration: 00:02:59

Innovations in Psychedelic Therapeutics and Pain Management at the Milken Conference

Cybin Inc. CEO Doug Drysdale will discuss drug development innovation and next-generation mental health treatments at the Milken Institute Global Conference. Meanwhile, Silo Pharma Inc. has reported positive preclinical data for its SP-26 Ketamine Implant for fibromyalgia and filed a patent application for SPC-14 targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease, showcasing advancements in pain management and cognitive health therapeutics.

Published: 2025-05-05 18:20:18

Duration: 00:04:02

Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder

In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the potential benefits of the two-hour treatment model for other compounds in development for depression treatment.

Published: 2024-06-26 07:33:22

Duration: 00:02:09

Exploring Ibogaine: A Breakthrough in Addiction Therapy with Deborah Mash, PhD

Join neuroscientist Deborah Mash, PhD, on 'Psychedelic Breakthrough Addiction Therapy' as she explores cutting-edge research on breakthrough addiction therapies, focusing on psychedelic medicines like Ibogaine. Dr. Mash, with thirty years of experience in addiction neuroscience, offers insight into groundbreaking therapies with the potential to transform lives. Tune in to CannabisRadio.com to learn more about the renaissance of psychedelic therapy for addiction treatment.

Published: 2024-06-25 15:23:52

Duration: 00:02:00

Exploring the Future of Psychedelic Therapy with Tryptamine Therapeutics Inc.

Join host Jonathan Jackson as he speaks with Tryptamine Therapeutics Inc. CEO Jason Carroll about the company's recent debut on the Australian Securities Exchange. Tryptamine Therapeutics is focused on developing an intravenous-infused psilocin formulation for psychedelic therapy, with core programs like TRP-8803 and TRP-8802 showing promising results in trials for conditions like fibromyalgia, IBS, and BED. Backed by a qualified Board and research partnerships, the company is set to begin groundbreaking clinical trials in Australia this quarter.

Published: 2024-06-05 13:07:25

Duration: 00:02:08